'DURVIT': a phase-I trial of single low-dose durvalumab (Medi4736) IntraTumourally injected in cervical cancer: safety, toxicity and effect on the primary tumour- and lymph node microenvironment.
J RotmanConstantijne H MomE S JordanovaT D de GruijlG G KenterPublished in: BMC cancer (2018)
NTR6119 , 1-nov-2016.